CriticalAntiretroviral, HIV protease inhibitor×Class III antiarrhythmic
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that breaks down dronedarone in the liver. Strong inhibitors of this enzyme raise dronedarone levels: ketoconazole increased them 17-fold (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Atazanavir also inhibits CYP3A4. In Europe it is taken with a booster: ritonavir, which inhibits this enzyme more strongly than atazanavir itself, or cobicistat, also a strong CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). Dronedarone levels may rise both with atazanavir/cobicistat and with ritonavir (atazanavir/cobicistat and ritonavir SmPCs, EMA). Dronedarone prolongs the QT and PR intervals on the electrocardiogram in a concentration-dependent way (dronedarone label, US Food and Drug Administration, FDA). Dronedarone itself is a moderate CYP3A4 inhibitor and a strong inhibitor of the transporter P-glycoprotein (EMA). But the documents give no data on its effect on atazanavir and no figures for this pair.
Symptoms
According to the ritonavir SmPC, higher dronedarone levels increase the risk of arrhythmias and other serious adverse reactions (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Dronedarone moderately prolongs the heart-rate-corrected QT interval (QTc), by about 10 ms. Proarrhythmic effects can occur with drugs that favour arrhythmias or with electrolyte disorders (dronedarone SmPC, EMA). In some people atazanavir prolongs the PR interval. Atrioventricular conduction changes are usually asymptomatic and generally limited to first-degree block, but second-degree block has also been reported (atazanavir label, US Food and Drug Administration, FDA). Dronedarone also prolongs PR (dronedarone FDA label). QT and PR prolongation show only on an electrocardiogram (ECG).
Management
The combination is contraindicated. In regimens with cobicistat, including the atazanavir/cobicistat tablet, dronedarone is contraindicated under that product's summary of product characteristics (atazanavir/cobicistat SmPC, European Medicines Agency, EMA). In regimens with ritonavir, the dronedarone documents contraindicate the combination. They name ritonavir among the strong CYP3A4 inhibitors that must not be taken with dronedarone, with no dose condition (dronedarone SmPC, EMA, and label, US Food and Drug Administration, FDA). The ritonavir documents list dronedarone among the contraindicated antiarrhythmics (ritonavir SmPC, EMA, and FDA label). Under the European SmPC, atazanavir is taken with low-dose ritonavir, and unboosted atazanavir 400 mg is kept only for restricted cases. Before starting a ritonavir-boosted regimen, check the ritonavir SmPC, because the ritonavir interaction profile may predominate (atazanavir SmPC, EMA). For unboosted atazanavir, the documents do not name this pair and do not class atazanavir itself as a strong CYP3A4 inhibitor (atazanavir SmPC, EMA, and FDA label). Use atazanavir with caution with drugs that prolong the PR interval, and take special precautions with drugs that may prolong the QT interval (atazanavir SmPC, EMA). During dronedarone treatment, the SmPC recommends monitoring that includes an electrocardiogram (ECG). Stop dronedarone if QTc reaches 500 ms or more, and correct low potassium or magnesium before and during treatment (dronedarone SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.2 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5